Tacton Appoints Klaus Andersen as CEO to Lead Next Phase of Global Growth
22.8.2025 15:00:00 CEST | Business Wire | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and leading SaaS platform simplifying sales and configuration processes for manufacturers of complex products, today announced that Klaus Andersen,currently serving as Chief Operating Officer, has been appointed Chief Executive Officer, effective August 21, 2025. He succeedsBo Gyldenvang,who is stepping down after leading the company through a pivotal and successful period of transformation and growth. Bo will remain an advisor to the company’s board of directors and executive leadership team.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250822177255/en/
Tacton CEO Klaus Andersen
Klaus brings with him more than two decades of executive leadership experience, with a distinguished track record of leadership and value creation. Prior to joining Tacton, Klaus served as CEO of several high-growth global technology companies, successfully leading multiple exits and delivering strong shareholder returns. His leadership has been defined by strategic clarity, customer-centricity, operational excellence, and building high-performance cultures.
Klaus has a long-standing relationship with Tacton—he served as Tacton’s Chairman of the Board for over two years,giving him a deep understanding of Tacton’s mission, vision, customers, and technology, which puts him in a very strong position to guide the company forward.
Since joining Tacton, Klaus has overseen major advancements in product innovation, customer engagement and investment to support the company’s continued growth. He has worked closely with Bo and the executive team to deepen Tacton’s relationships with global manufacturing leaders, streamline internal operations, and position the company for long-term success.
“I am incredibly honored to step into the role of CEO at such an exciting time for Tacton,” said Klaus Andersen. “We are uniquely positioned to lead the next generation of manufacturing transformation through our innovative CPQ platform, deep industry expertise, and incredible team. I look forward to partnering with our customers, employees, and stakeholders as we write the next chapter of growth and impact.”
Bo Gyldenvang added, “It has been a privilege to lead Tacton and work alongside such talented and passionate people for the past five years. While stepping away is bittersweet, I’m thrilled and extremely confident in Klaus taking the helm and guiding the company forward in its next phase of global growth. His vision, experience, and drive make him the ideal CEO for Tacton’s future.”
The appointment comes at a time of strong momentum for Tacton, following continued customer growth, product innovation, strategic partnerships, and recognition as a Leader for the third consecutive time in the 2025 Gartner® Magic Quadrant™ for Configure, Price, Quote Applications.
About Tacton
Tacton is a leading SaaS company, redefining CPQ buyer engagement for manufacturers of complex products. By streamlining the buyer journey, Tacton empowers manufacturers to accelerate go-to-market strategies, increase sales, and build brand loyalty. Trusted since 1998 by global leaders such as ABB, Daimler, MAN, Scania, Siemens, Xylem, and Yaskawa, Tacton continues to drive innovation in manufacturing. The company is co-headquartered in Chicago and Stockholm, with regional offices in Karlsruhe, Warsaw, and Tokyo. Learn more at www.tacton.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250822177255/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom